Although several novel agents have been implemented in the treatment of Hodgkin and non-Hodgkin lymphoma (HL; NHL), chemotherapy remains the backbone of treatment, both in the frontline and relapsed settings.

In this podcast, you will hear from Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, who shares some insights into the current role of chemotherapy in HL and various subtypes of NHL, and further explains how novel therapies, including CAR-T cells and antibodies, are changing the treatment landscape of these diseases.